证券日报网讯12月10日，何氏眼科（301103）在互动平台回答投资者提问时表示，公司在智能化系统眼 科应用方面，整合了智能算法辅助诊断系统，建设眼科专科智能影像云平台，开发多模态数据融合决策 系统，并生成3D眼健康数字孪生模型。通过深度算法助力健康管理，"何氏糖管家"基于智能技术中的 深度学习算法，利用动态血糖监测设备，实时监测并传输血糖级别至云端，通过云端数据分析、医患交 互平台及个性化健康管理方案，旨在实现糖尿病患者全生命周期的精准控糖与眼病防控。此外何氏眼 科"光明小屋"以眼科智能设备为入口，结合线上和线下的眼科诊疗系统，通过先进的智能诊断，发现眼 部疾病和慢性疾病，打造数字智能技术赋能基层眼健康管理的数字场景。在角膜塑形镜验配领域，公司 基于智能算法建立了VST设计的算法模型，通过深度学习提高验配效率。以上业务对公司当前主营业务 开展或业绩未造成重大影响，如有重大进展或者触及信息披露标准，会按照监管要求履行信息披露义 务，敬请谨慎决策、注意投资风险。 ...

Core Viewpoint - He Eye Hospital (301103) has appointed Mr. He Xingru as the new general manager, who will be responsible for the company's daily operations and management [1] Group 1: Company Strategy - The company will adhere to the "Technology and Humanity" philosophy and deepen the "Smart Bright City" strategy [1] - There is a focus on integrating cutting-edge technologies such as digitalization and precision medicine with ophthalmic healthcare [1] - The aim is to establish a comprehensive life-cycle eye health management system [1] Group 2: Long-term Vision - The company believes that a stable long-term market value is derived from solid operational performance and clear value logic [1] - Future strategies will emphasize sustainable development, transparent information disclosure, and effective communication with investors [1] - The company aims to steadily advance its brand building in the capital market and create long-term value for investors [1] Group 3: Future Reporting - Stakeholders are encouraged to pay attention to the company's upcoming periodic reports for specific operational updates [1]

Core Insights - The company is focusing on integrating intelligent systems in ophthalmology, including the development of a smart imaging cloud platform and a multi-modal data fusion decision system, aimed at enhancing health management for diabetes patients and eye disease prevention [1] - The third quarter report for 2025 shows a revenue of 295 million yuan, a year-on-year increase of 5.37%, and a net profit attributable to shareholders of 10.07 million yuan, a significant increase of 230.99% [1] - For the first three quarters of 2025, the company reported a revenue of 855 million yuan, a year-on-year decrease of 1.11%, while the net profit attributable to shareholders was 54.40 million yuan, reflecting a year-on-year increase of 232.18% [2] Group 1 - The company has developed a diabetes management system called "He’s Sugar Manager," which utilizes deep learning algorithms and real-time blood glucose monitoring to provide personalized health management solutions [1] - The "Bright House" initiative combines online and offline ophthalmic diagnostic systems to enhance the detection of eye and chronic diseases through advanced intelligent diagnostics [1] - The company has established an algorithm model for orthokeratology lens fitting based on intelligent algorithms, improving fitting efficiency through deep learning [1] Group 2 - The company has implemented measures to improve the quality and efficiency of medical services, optimize the supply chain, and reduce operational costs, contributing to its financial performance [2] - The focus on high-margin refractive and optometry businesses has been a key strategy in the company's ongoing development [2]

Core Viewpoint - He Eye Hospital (301103) emphasizes its commitment to providing fair access to information for all investors by disclosing shareholder information in regular reports [1] Group 1 - The company will disclose shareholder information at specific reporting periods in its regular reports [1] - For inquiries regarding shareholder numbers at other times, shareholders must provide written proof of their shareholding type and quantity [1] - The company will verify shareholder identity before providing the requested information [1]

Core Viewpoint - He Eye Hospital (301103) has seen a significant increase in financing activities, with a net financing purchase of 128.21 million yuan on December 5, 2025, indicating strong investor interest and confidence in the stock [1][2]. Financing Activities Summary - On December 5, 2025, the financing buy-in amounted to 437.04 million yuan, while financing repayment was 308.83 million yuan, resulting in a net financing purchase of 128.21 million yuan [1]. - The financing balance reached 6864.65 million yuan, with a net financing purchase of 382.06 million yuan over the last three trading days [1]. - In the past 20 trading days, there were 14 days with net financing purchases, reflecting consistent demand for the stock [1]. Daily Financing Data - On December 5, 2025, the net financing purchase was 128.21 million yuan, with a financing balance of 6864.65 million yuan, representing 2.17% of the circulating market value [2]. - The financing balance has shown a steady increase, with a rise of 1.9% on December 5 compared to the previous day [3]. - The financing balance has increased from 6301.00 million yuan on December 1 to 6864.65 million yuan on December 5, indicating a positive trend in investor engagement [2][3].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：301103 证券简称：何氏眼科 公告编号：2025-048 辽宁何氏眼科医院集团股份有限公司 关于变更公司总经理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 一、总经理离任情况 辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）董事会于近日收到公司董事长、总经理何伟先 生辞去总经理职务的申请，为了顺应《上市公司治理准则（2025年10月修订）》做好分权安排并确保公 司独立的相关要求，同时结合公司业务的不断发展，需要战略决策与经营管理合理分工，何伟先生将更 专注于履行董事长职责，集中精力统筹公司长期战略规划与发展方向，进一步优化公司治理结构、提升 决策效率，保障上市公司独立性，申请辞去公司总经理职务，其申请自送达董事会之日起生效。何伟先 生辞去总经理职务后，仍继续担任公司第三届董事会董事长、董事会战略与可持续发展委员会主任委 员、董事会提名委员会委员。何伟先生原定任期至第三届董事会届满之日止，其辞职不会对公司日常经 营产生不利影响。 截至本公告披露之日，何伟先生直接持有公司股份30,327 ...

Core Insights - He Eye Hospital Group has been awarded the "2025 Listed Company ESG Value Transmission Award" and the "2025 Listed Company AI Frontier Innovation Award" at the recent China AI Track and ESG Sustainable Development Conference, recognizing its efforts in ESG value transmission and AI applications in ophthalmology [1][3] Group 1: ESG and Social Responsibility - He Eye Hospital has actively fulfilled its social responsibilities and practiced sustainable development by building a human-centered eye health system through advocacy, capacity building, treatment rehabilitation, charity, and public education [2] - The hospital has trained over 50,000 grassroots doctors and eye health management personnel as a training base for the National Health Commission's blindness prevention and treatment initiatives [2] Group 2: Technological Innovation and Strategy - Under the "Technology Empowering Eye Health" strategy, He Eye Hospital aims to reduce costs, increase efficiency, and expand boundaries by deeply integrating digital transformation with AI technology [2] - The hospital has established an intelligent system covering the entire medical chain, focusing on four core goals: data asset accumulation, service experience enhancement, medical efficiency breakthroughs, and ecological collaboration deepening [2] Group 3: Future Focus and International Cooperation - The company plans to continue focusing on gene therapy, stem cell medicine, and smart healthcare, promoting the deep integration of new technologies like AI with clinical needs [3] - He Eye Hospital aims to enhance its international cooperation and public welfare practices to convey ESG values in the field of eye health [3]

Core Points - He Eye Hospital announced the resignation of its General Manager, He Wei, who will continue to serve as the Chairman of the Board and other committee roles [1] - The Board of Directors has appointed He Xingru as the new General Manager, responsible for daily operations [1] Company Changes - He Wei's resignation is part of a strategy to enhance decentralization and ensure the company's independence [1] - He Xingru's appointment as General Manager is effective immediately following the Board's approval and will last until the current Board's term ends [1]

Core Insights - He Eye Hospital has been awarded the "2025 Annual Listed Company ESG Value Transmission Award" and the "2025 Annual Listed Company AI Frontier Innovation Award" for its continuous efforts in ESG value transmission and pioneering applications of artificial intelligence in ophthalmology [1] Group 1: ESG Commitment - He Eye Hospital has been dedicated to the field of eye health for 30 years, focusing on prevention and treatment, and providing specialized ophthalmic diagnosis and vision care services [2] - As of June 30, 2025, the company operates 127 ophthalmic service institutions across key regions in China, aligning with the "Healthy China" strategy and the United Nations Sustainable Development Goals [2] - The company has trained over 50,000 grassroots doctors and eye health management personnel, contributing to a people-centered eye health system [2] Group 2: AI Innovations - The recognition of the AI Frontier Innovation Award highlights He Eye Hospital's technological innovation and clinical implementation capabilities in smart healthcare [3] - The company has integrated AI technology into its operations, enhancing efficiency in data collection and analysis, and optimizing clinical services through an AI imaging cloud platform [3] - The "He Diabetes Manager" utilizes AI deep learning algorithms for real-time blood sugar monitoring, aiming for precise diabetes management and eye disease prevention [3] Group 3: Refractive Surgery Advancements - In the field of refractive surgery, AI technology is applied to create personalized models for corneal aberration data, shifting surgical decision-making from experience-based to data-driven [4] - AI technology aids in preoperative risk assessment by intelligently analyzing eye images, enhancing surgical safety and control [4] - The integration of AI with visualization systems allows for better patient experience by presenting postoperative outcomes and optimizing surgical processes [4]

Core Viewpoint - The company announces a leadership change, with the current General Manager resigning due to governance and business development needs, while remaining as Chairman [1] Group 1 - The Chairman and General Manager, He Wei, has applied for resignation from the General Manager position [1] - He Wei will continue to serve as the Chairman of the company after his resignation [1] - The board of directors has approved the appointment of He Xingru as the new General Manager, effective from the date of the board's approval until the end of the third board's term [1]